Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
47
TERN Quote, Financials, Valuation and Earnings
Last price:
$41.55
Seasonality move
:
-23.71%
Day range:
$41.41 - $42.53
52-week range:
$1.87 - $48.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
13.17x
Volume:
974.2K
Avg. volume:
4.5M
1-year change:
606.12%
Market cap:
$3.7B
Revenue:
--
EPS (TTM):
-$1.03
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TERN
Terns Pharmaceuticals, Inc.
|
-- | -$0.30 | -- | -27.21% | $53.56 |
|
ADMA
ADMA Biologics, Inc.
|
$145.4M | $0.20 | 18.97% | -56.04% | $25.67 |
|
ALT
Altimmune, Inc.
|
$830 | -$0.27 | -88.8% | -25.34% | $17.75 |
|
CDTX
Cidara Therapeutics, Inc.
|
-- | -$1.64 | -100% | -71.79% | $221.50 |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$60.1M | $1.82 | 29.84% | -74.47% | $243.44 |
|
VKTX
Viking Therapeutics, Inc.
|
-- | -$0.94 | -- | -182.02% | $93.39 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TERN
Terns Pharmaceuticals, Inc.
|
$41.52 | $53.56 | $3.7B | -- | $0.00 | 0% | -- |
|
ADMA
ADMA Biologics, Inc.
|
$19.28 | $25.67 | $4.6B | 22.64x | $0.00 | 0% | 9.71x |
|
ALT
Altimmune, Inc.
|
$3.86 | $17.75 | $402.8M | -- | $0.00 | 0% | 15,329.22x |
|
CDTX
Cidara Therapeutics, Inc.
|
$220.80 | $221.50 | $6.9B | -- | $0.00 | 0% | 55.23x |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$195.83 | $243.44 | $3.9B | 94.25x | $0.00 | 0% | 15.34x |
|
VKTX
Viking Therapeutics, Inc.
|
$37.18 | $93.39 | $4.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TERN
Terns Pharmaceuticals, Inc.
|
0.36% | 0.860 | 0.16% | 19.21x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
ALT
Altimmune, Inc.
|
7.89% | 0.693 | 4.41% | 16.79x |
|
CDTX
Cidara Therapeutics, Inc.
|
0.47% | 3.325 | 0.07% | 4.47x |
|
LGND
Ligand Pharmaceuticals, Inc.
|
32.19% | 1.626 | 12.95% | 23.64x |
|
VKTX
Viking Therapeutics, Inc.
|
0.11% | 1.448 | 0.03% | 27.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TERN
Terns Pharmaceuticals, Inc.
|
-$111K | -$27.7M | -28.94% | -29.05% | -- | -$19.8M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ALT
Altimmune, Inc.
|
-$22K | -$20.9M | -53.6% | -56.24% | -417180% | -$11.9M |
|
CDTX
Cidara Therapeutics, Inc.
|
-$28K | -$43.6M | -68.01% | -68.74% | -3675.83% | -$40.6M |
|
LGND
Ligand Pharmaceuticals, Inc.
|
$103.6M | $54.1M | 5.15% | 5.72% | 46.85% | $4.8M |
|
VKTX
Viking Therapeutics, Inc.
|
-$114K | -$98.6M | -28.59% | -28.62% | -- | -$94M |
Terns Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns TERN or ADMA?
ADMA Biologics, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of 27.14%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About TERN or ADMA?
Terns Pharmaceuticals, Inc. has a consensus price target of $53.56, signalling upside risk potential of 28.99%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 33.13%. Given that ADMA Biologics, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Terns Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TERNTerns Pharmaceuticals, Inc.8 0 0 ADMAADMA Biologics, Inc.3 0 0 -
Is TERN or ADMA More Risky?
Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock TERN or ADMA?
Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TERN or ADMA?
Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 22.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 9.71x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M ADMAADMA Biologics, Inc.9.71x 22.64x $134.2M $36.4M
-
Which has Higher Returns TERN or ALT?
Altimmune, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of -380280%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Altimmune, Inc.'s return on equity of -56.24%.
Company Gross Margin Earnings Per Share Invested Capital TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M ALTAltimmune, Inc.-440% -$0.21 $201.5M -
What do Analysts Say About TERN or ALT?
Terns Pharmaceuticals, Inc. has a consensus price target of $53.56, signalling upside risk potential of 28.99%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.75 which suggests that it could grow by 359.85%. Given that Altimmune, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Altimmune, Inc. is more attractive than Terns Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TERNTerns Pharmaceuticals, Inc.8 0 0 ALTAltimmune, Inc.5 1 1 -
Is TERN or ALT More Risky?
Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of -0.029, suggesting its less volatile than the S&P 500 by 102.89%.
-
Which is a Better Dividend Stock TERN or ALT?
Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TERN or ALT?
Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Altimmune, Inc. quarterly revenues of $5K. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is lower than Altimmune, Inc.'s net income of -$19M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 15,329.22x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M ALTAltimmune, Inc.15,329.22x -- $5K -$19M
-
Which has Higher Returns TERN or CDTX?
Cidara Therapeutics, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of -30201.66%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.
Company Gross Margin Earnings Per Share Invested Capital TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M CDTXCidara Therapeutics, Inc.81.53% -$3.10 $424.4M -
What do Analysts Say About TERN or CDTX?
Terns Pharmaceuticals, Inc. has a consensus price target of $53.56, signalling upside risk potential of 28.99%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.32%. Given that Terns Pharmaceuticals, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Terns Pharmaceuticals, Inc. is more attractive than Cidara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TERNTerns Pharmaceuticals, Inc.8 0 0 CDTXCidara Therapeutics, Inc.1 6 0 -
Is TERN or CDTX More Risky?
Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.073%.
-
Which is a Better Dividend Stock TERN or CDTX?
Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TERN or CDTX?
Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Cidara Therapeutics, Inc. quarterly revenues of --. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M CDTXCidara Therapeutics, Inc.55.23x -- -- -$83.2M
-
Which has Higher Returns TERN or LGND?
Ligand Pharmaceuticals, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of 10.18%. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Ligand Pharmaceuticals, Inc.'s return on equity of 5.72%.
Company Gross Margin Earnings Per Share Invested Capital TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M LGNDLigand Pharmaceuticals, Inc.89.7% $5.68 $1.4B -
What do Analysts Say About TERN or LGND?
Terns Pharmaceuticals, Inc. has a consensus price target of $53.56, signalling upside risk potential of 28.99%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $243.44 which suggests that it could grow by 24.31%. Given that Terns Pharmaceuticals, Inc. has higher upside potential than Ligand Pharmaceuticals, Inc., analysts believe Terns Pharmaceuticals, Inc. is more attractive than Ligand Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TERNTerns Pharmaceuticals, Inc.8 0 0 LGNDLigand Pharmaceuticals, Inc.6 0 0 -
Is TERN or LGND More Risky?
Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.587%.
-
Which is a Better Dividend Stock TERN or LGND?
Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TERN or LGND?
Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Ligand Pharmaceuticals, Inc. quarterly revenues of $115.5M. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is lower than Ligand Pharmaceuticals, Inc.'s net income of $117.3M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Ligand Pharmaceuticals, Inc.'s PE ratio is 94.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus 15.34x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M LGNDLigand Pharmaceuticals, Inc.15.34x 94.25x $115.5M $117.3M
-
Which has Higher Returns TERN or VKTX?
Viking Therapeutics, Inc. has a net margin of -- compared to Terns Pharmaceuticals, Inc.'s net margin of --. Terns Pharmaceuticals, Inc.'s return on equity of -29.05% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.
Company Gross Margin Earnings Per Share Invested Capital TERNTerns Pharmaceuticals, Inc.-- -$0.27 $285.1M VKTXViking Therapeutics, Inc.-- -$0.81 $713.8M -
What do Analysts Say About TERN or VKTX?
Terns Pharmaceuticals, Inc. has a consensus price target of $53.56, signalling upside risk potential of 28.99%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 151.18%. Given that Viking Therapeutics, Inc. has higher upside potential than Terns Pharmaceuticals, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Terns Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TERNTerns Pharmaceuticals, Inc.8 0 0 VKTXViking Therapeutics, Inc.12 1 0 -
Is TERN or VKTX More Risky?
Terns Pharmaceuticals, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.
-
Which is a Better Dividend Stock TERN or VKTX?
Terns Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TERN or VKTX?
Terns Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Viking Therapeutics, Inc. quarterly revenues of --. Terns Pharmaceuticals, Inc.'s net income of -$24.6M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Terns Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals, Inc. is -- versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TERNTerns Pharmaceuticals, Inc.-- -- -- -$24.6M VKTXViking Therapeutics, Inc.-- -- -- -$90.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
